Products with Adrenergic receptor blockers bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1424 | Hordenine |
| Hordenine is an inhibitor of noradrenaline uptake, is also an effective inhibitor of hyperpigmentation. It can inhibit melanogenesis by suppressing cAMP production, which is involved in the expression of melanogenesis-related proteins. Hordenine also has a positive inotropic effect upon the heart, increases systolic and diastolic blood pressure, peripheral blood flow volume, inhibits gut movements. | |
| BCN1441 | 14-Deoxy-11,12-didehydroandrographolide |
| 14-Deoxy-11,12-didehydroandrographolide has hypotensive, anti-inflammatory, anti-asthma, and anti-cancer actions, it causes negative chronotropic action and antagonised isoproterenol-induced positive chronotropic actions in a non-competitive and dose-dependent manner. 14-Deoxy-11,12-didehydroandrographolide can effectively ameliorate astrocytic pro-inflammatory reactions and prevent PC12 cell death with different efficacies, it may be candidates for treatment of spinal-cord injury and neurodegeneration. | |
| BCN1868 | Anisodine |
| 1. Anisodine is a traditional anticholinergics. 2. Anisodine can protect optic nerve of primary open angle glaucoma (POAG) through improving the visual function and blood supply of optic nerve. 3. The combination of Anisodine and citicoline with standard steroid and mannitol therapy appears to be effective in the treatment of early optic nerve contusion. 4. Anisodine and anisodamine possess alpha 1-adrenoceptor blocking properties, they are widely used in the People's Republic of China for the management of acute circulatory shock . | |
| BCN2164 | Silodosin |
| 1. Silodosin, a selective α-1a receptor antagonist, can increase passage of distal ureteral stones. 2. Silodosin can temporarily improve lower urinary tract symptoms (LUTS), but do not improve the bladder outlet obstruction index (BOOI) after implantation in the prostate, it is a useful option for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia . 3. Silodosin appears to suppress ejaculation in a relatively higher percent of trial participants, this suppression of ejaculation by silodosin suggested its potential for treating premature ejaculation. | |
